New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
08:16 EDTTEVA, ALXATeva launches ADASUVE in U.S.
Teva Pharmaceutical (TEVA) announced the commercial launch of ADASUVE inhalation powder 10 mg, the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE is administered through Alexza Pharmaceuticals' (ALXA) innovative proprietary Staccato single-use, hand held drug delivery technology system. This new drug-device combination product provides rapid systemic delivery by inhalation of a thermally-generated aerosol of loxapine, a first generation antipsychotic, to the lung. Administration of ADASUVE results in rapid absorption of loxapine, with a maximum plasma concentration achieved in approximately 2 minutes. Efficacy was demonstrated in two clinical trials in acute agitation: one in schizophrenia and one in bipolar I disorder. Patients receiving ADASUVE experienced a statistically significant reduction in agitation at two hours, with an effect seen as early as ten minutes post-dose.
News For TEVA;ALXA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:11 EDTTEVATeva reported great Q3 results, says BMO Capital
Subscribe for More Information
09:06 EDTTEVATeva says assessing M&A opportunities of all sizes
08:49 EDTTEVATeva says may pursue generic businesses in emerging markets
Says not ruling out "transformational" transactions. Says open to specialty assets in U.S., Europe.
08:40 EDTTEVATeva says $5.00-$5.10 FY14 EPS guidance is for exclusive Copaxone scenario
Subscribe for More Information
07:06 EDTTEVATeva board authorizes increase in share repurchase program to $3B
The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.
07:05 EDTTEVATeva raises FY14 EPS view to $5.00-$5.10 from $4.90-$5.10
Subscribe for More Information
07:05 EDTTEVATeva reports Q3 EPS $1.32, consensus $1.23
Subscribe for More Information
October 27, 2014
09:07 EDTALXAAlexza Pharmaceuticals and Ferrer expand Adasuve partnership
Alexza Pharmaceuticals announced that they have amended their agreement for ADASUVE. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America and the Commonwealth of Independent States countries. Ferrer and Alexza have agreed that Ferrer will purchase 2M shares of Alexza common stock for $4.00 per share, thereby becoming the company's largest shareholder. The purchase represents a combination of new investment and consideration for the elimination of certain future potential milestone payments under the agreement.
07:22 EDTTEVAAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 20, 2014
06:28 EDTTEVAAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use